BMS recalls blood-pressure drug Avalide; Sun gets tentative OK for Crestor copy;

 @FiercePharma: Chief Justice unloads Pfizer shares. Article | Follow @FiercePharma

From the archives: Top 10 Pharma CEO salaries of 2009. Report

> Bristol-Myers Squibb is recalling 60 million tablets of the blood pressure medication Avalide in the U.S. and Puerto Rico. Report

> Sun Pharmaceutical Industries won tentative marketing approval for a generic version of AstraZeneca's cholesterol drug Crestor. Report

> Novartis lost a U.K. appeal to overturn a ruling that invalidated its European patent for extended-wear contact lenses in a lawsuit against Johnson & Johnson. Report

> A Maryland couple has filed a wrongful death lawsuit against Pfizer, saying that a switch in formulation for its Dilantin epilepsy drug caused their son's death. Report

> GlaxoSmithKline has tapped soccer star Mia Hamm for its public health campaign to emphasize the need for adults to make vaccinations part of their overall health-and-wellness goals. Report

> Regulators approved the wider use of GlaxoSmithKline's clot-busting medicine Arixtra (fondaparinux) throughout the European Union. Report

> Marketing rights for cancer treatment Caeylx outside the U.S. will be returned to Janssen from Merck after a licensing deal expires in December. Report

> Warner Chilcott has completed the sale of $500 million in debt to finance its acquisition of the U.S. rights to the bladder treatment Enablex. Report

> AstraZeneca Pharma India said its public shareholders did not approve a special resolution to delist the company from the stock exchanges, leading its shares to fall more than 3 percent. Report

Biotech News

 @FierceBiotech: Lilly research chief outlines the perfect biotech pact. Article | Follow @FierceBiotech

 @JohnCFierce: Genzyme's Termeer says he's ready to go, when the price and time is right. But don't look for a snap deal with Sanofi. Report |  Follow @JohnCFierce

> HIV vax researchers ponder best R&D strategies in Atlanta. Article

> Protox lines up $35M for BPH program. Story

> Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial. Report

> Sanofi pipeline review overshadowed by Genzyme maneuvers. Item

Vaccines News

> Withdrawn Sanofi Hep B vax continues to help kids. Story

> HIV vaccine researchers ponder new strategies, drop in funding. Article

> HHS chief promises cell-based flu vax in 2011. News

> Vax experts discuss trials, tribulations of malaria R&D. Report

Manufacturing News 

> Xcelience boosts solid oral dosage form capabilities. News

> Lannett and Cody pass FDA muster. Story

> Service calculates API-making costs for generics. News

> India finds execs liable for manufacturing defects. Report

And Finally... A nationwide shortage of several widely used anesthetics, which has been exasperating doctors and veterinarians for months, has now spread to the country's death rows. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.